Diabetes drug could shield kidneys in rare disease
NCT ID NCT06090227
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the diabetes drug metformin can protect kidney cells in people with a rare kidney disease called FSGS. About 30 adults will receive either metformin or a placebo for 6 months, alongside their usual treatments. The goal is to see if metformin reduces kidney damage and helps preserve kidney function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mount Sinai Hospital
RECRUITINGNew York, New York, 10029, United States
-
Yale New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Kidney disease mystery: scientists launch massive data hunt
- Scientists hunt for genes behind kidney disease
- New drug aims to plug kidney leaks in multiple diseases
- New pill aims to plug protein leak in kidney patients
- New biobank aims to unlock why kidney disease returns after transplant
- Ear-Zap therapy could spare kids from harsh kidney drugs